ISRCTN - ISRCTN06273186: The effect of a newly developed patch treatment for disc hernia

Plain English Summary

Background and study aims
Treatment of low back pain and neck pain in cases of disc hernia involves drugs, physical
therapy and surgery in severe cases. This new drug is a patch that is easy to apply by sticking onto the skin. The aim of this study is to find out if this patch treatment is effective in reducing low back pain or neck pain due to disc hernia.

Who can participate?
Any patient suffering from back and neck pain aged between 20 to 60 years can take part in the study. Healthy volunteers of the same age range can also take part in the study.

What does the study involve?
Patients will be given the patch treatment if the pain is not resolved by drugs or physical therapy. We will also give the patch to healthy participants for comparison. Participants will have to rest completely during treatment. Pain before and after the treatment will be measured. Patients will also undergo a magnetic resonance examination before and after the treatment.

What are the possible benefits and risks of participating?
The most important side effect of the treatment is local rash in the skin where the patch is attached. There are no other side effects expected from the patch.

Where is the study run from?
Neurosurgery Department of Yildirim Beyazit Education and Research Hospital, Turkey.

When is study starting and how long is it expected to run for?
The study will run between January 2014 and February 2014.

Who is funding the study?
Metuas Medical Company, Turkey.

Who is the main contact?
Dr Mehmet Sorar
msorar@gmail.com

Trial website

Contact information

Type

Scientific

Primary contact

Dr Gulsah Bayram Kabacam

ORCID ID

Contact details

Bagcilar Mah. Acin Cad. 281. Sok 3/10 GOP
Ankara
06670
Turkey

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

ARTC0001CL

Study information

Scientific title

A pilot controlled study on the efficacy of a diffusional patch (ArtCure®) for the treatment of disc hernia

Acronym

Study hypothesis

Artcure diffusional patch is safe and effective for the treatment of disc hernia.

Ethics approval

Kecioren Education and Research Hospital board of ethics, 15/03/2012, ref: 15.03.2012/B.10.4.İSM.4.06/68/49

Study design

Single-center controlled trial

Primary study design

Interventional

Secondary study design

Non randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Disc hernia/low back pain/neck pain

Intervention

Artcure patch treatment with complete bed rest in disc hernia and healthy control cases.

All of the cases admitted to the hospital with cervical or lumbar disc herniation that is resistant to medical and physical therapy will be taken into the study if they fill in the informed consent form. Pre-treatment neurological examination and semi-quantitative, subjective pain assessment using the Visual Analog Scale (VAS) scoring from 0 (no pain) to 10 (most severe pain) will be carried out. Diagnosis and extent of the hernia will be confirmed by MRI examination. The Artcure® diffusional patch will be attached to the level of herniation, taking care that the central part of the patch is at the same level as the hernia. Patients then have 24 hours of absolute bed rest. At the end of this period the patch will be removed. Post-treatment assessment will be comprised of a second neurological examination. VAS scores for pain assessment will be determined 24 and 48 hours after the treatment. Control MRI examinations with the same sequences will be done in 6-8 weeks post-treatment.

Intervention type

Other

Phase

Not Applicable

Drug names

Primary outcome measures

1. Complete resolution of the pain [48 hours post-treatment visual analogue scale (VAS) score = 0]
2. More than 5 points decrease in the VAS score in the 48 hours post-treatment
3. Complete resolution of the neurologic deficit in 48 hours

Secondary outcome measures

1. VAS and neurological examinations will be performed at the baseline, 24 and 48 hours after the treatment
2. Pre- and post-treatment MRIs will be taken before the treatment and 6-8 weeks after the treatment

Overall trial start date

01/01/2014

Overall trial end date

01/02/2014

Reason abandoned

Eligibility

Participant inclusion criteria

1. Patients with severe low back or neck pain due to disc hernia between the ages of 20 and 60 who are willing to take part
2. Age-matched healthy control cases without low back pain and disc hernia

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

40 patients and 40 control cases

Participant exclusion criteria

1. Severe para-vertebral muscle spasm
2. Lumbar spinal stenosis
3. Foraminal stenosis
4. Calcified lumbar or cervical hernia
5. Loss of cervical or lumbar lordosis accompanying disc hernia
6. Loss of strength in any muscle group more than 2/5
7. Known dermal atophy
8. Accompanying asthma

Recruitment start date

01/01/2014

Recruitment end date

01/02/2014

Locations

Countries of recruitment

Turkey

Trial participating centre